Kevin Moreau

Kevin Moreau

Company: AstraZeneca

Job title: Associate Director


Panel Discussion: What Makes a Good Degrader? 4:00 pm

There is a current lack of protocols for making a successful degrader with good chemical matter. Being able to determine the parameters for what good look like and establishing common determinants will help the fast track development of the next generation of degraders. During the panel these key topics will be discussed: Understanding why early…Read more

day: Day Two

Round Table Discussion: How to Maximise the Safety Profile to Achieve Efficient Degradation 12:30 pm

What are the current strategies to effectively scale up material for toxicity studies? How to optimise the safety profile to progress into the clinicRead more

day: Day 1 AM - Stream B

PROTAC Safety Perspective, Consideration For Oncology/Non-Oncology Indications 12:00 pm

What are the potential PROTAC safety liabilities? Can we optimise the safety profile? What is an acceptable safety profile of non-oncology targets? How can we profile PROTAC at scale?Read more

day: Day 1 AM - Stream B

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.